“This quarter, we’ve continued to make significant advancements across our pipeline to bring forward a potential backbone bladder-sparing therapy for patients with Non-Muscle Invasive Bladder Cancer,” said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology (CGON). “As we reported earlier this year at the AUA and ASCO annual meetings, cretostimogene has the ability to induce a sustained and durable complete response in bladder cancer patients with a strong safety and tolerability profile. We believe that cretostimogene’s unique product profile differentiates it from current and investigational NMIBC treatments, and we look forward to sharing updated results from our BOND-003 registrational study at SUO.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology announces publication in Nature Medicine of Phase 1b results
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- CG Oncology initiated with a Buy at UBS
- J&J trial miss may be viewed positively for CG Oncology, says BofA
- enGene price target lowered to $17 from $26 at Leerink